Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Generic: Semaxanib
SU5416 is a small molecule tyrosine kinase inhibitor that specifically targets vascular endothelial growth factor receptor-2 (VEGFR-2). It was initially developed as an anti-cancer agent but showed limited efficacy in clinical trials. However, SU5416 has become a valuable tool in preclinical research for inducing pulmonary arterial hypertension (PAH) in animal models, mimicking the human disease's pathophysiology.
Used primarily in preclinical research to induce pulmonary arterial hypertension (PAH) in animal models.
Outcome:
Increased risk of bleeding and impaired wound healing
Mechanism:
Synergistic inhibition of angiogenesis
Outcome:
Increased risk of gastrointestinal bleeding
Mechanism:
Additive effects on gastric mucosa
Outcome:
Reduced absorption of SU5416
Mechanism:
Changes in gastric pH
Potential future use of SU5416 or its analogs may lie in targeted therapies for specific PAH subtypes (2025, 50% confidence).
Due to limited clinical efficacy, SU5416 is unlikely to receive FDA approval for cancer treatment.
Tyrosine Kinase Inhibitor, VEGFR-2 Inhibitor
Indolinone